Search
Displaying 101–110 of 779 for “retinitis clinical trial”
-
Retinal Patch Performs Promisingly in Clinical Trial for Dry AMD Patients
Research NewsRegenerative Patch Technologies, a company developing stem-cell-derived treatments for people with retinal diseases, has reported encouraging results for the first five patients with advanced, dry age-related macular degeneration (AMD) participating in a Phase I/IIa clinical trial for its therapy – a patch comprised of a layer of retinal pigment epithelial (RPE) cells on a synthetic scaffold.
-
Vision Improvements Reported in ProQR's Clinical Trial for LCA10 Treatment
Research NewsThe company reported that 60 percent of subjects in the trial demonstrated improvements in visual acuity and their ability to navigate a mobility course. The treatment was also safe for patients.
-
Wet AMD Treatment Susvimo Preserves Vision for Five Years in Phase 3 Clinical Trial
Research NewsSusvimo is an FDA-approved treatment that continuously delivers drug through a tiny, implanted capsule
-
Encouraging Early Report for Three Patients in LCA1-GUCY2D Gene Therapy Clinical Trial
Research NewsDevelopment of the emerging gene therapy is being funded by the Foundation’s RD Fund
-
Positive Interim Clinical Trial Results for Adverum’s Wet AMD Gene Therapy
Research NewsThe gene therapy is designed to reduce the treatment burden for patients
-
Apellis Launches Phase 3 Clinical Trial Program for Advanced Dry AMD Treatment
Research NewsTrial participants will receive intravitreal injections of APL-2, or a sham procedure (placebo), monthly or every other month. The injections are made into the vitreous, the soft gel in the middle of the eye.
-
Editas Reports Results for 14 Participants in its Phase 1/2 CRISPR/Cas9 Clinical Trial for LCA10
Research NewsThe company is seeking a partner to move the LCA10 program forward
-
Ascidian to Launch Clinical Trial for Stargardt Disease RNA Editing Therapy
Research NewsACDN-01 is the only genetic medicine entering clinical development for Stargardt disease.
-
Research News
The company is planning a late-stage trial for its achromatopsia (CNGB3) gene therapy.
-
Ocugen Launches Phase 2/3 Clinical Trial for Stargardt Disease Gene-Modifier Therapy
Research NewsThe therapy delivers copies of the RORA gene to address multiple disease pathways.
